Search Results

Ocean Biomedical, Inc. announces that the company and Polar Multi-Strategy Master Fund entered into a Side Letter related to the Forward Purchase Agreement entered into in February 2023.

The global lipid nanoparticles market revenue reached US$ 820.51 million in 2023 and is estimated to reach a market valuation of US$ 2,387.98 million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 12.6% during the forecast period from 2024 to 2032.

Avanti combining with Croda to expand life sciences products, pharmaceutical services and cGMP production capabilities for biotechnology, pharmaceutical and life science research customers globally Avanti will continue to operate under the Avanti brand and be led by the current management team [06-July-2020] ALABASTER, Alabama , July 6, 2020 /PRNewswire/ --

Global Lipid Nanoparticles (LNPs) CDMO Market in terms of revenue was predicted to be worth $182.0 Mn in 2023 and is poised to reach 518.2 Mn by 2031, increasing at a CAGR of 14.10% from 2024 to 2031.

Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk of adverse cardiovascular outcomes.

Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates.